专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010042525A9 OVARIAN CANCER BIOMARKERS AND USES THEREOF 审中-公开
标题翻译：卵巢癌生物标志物及其用途
公开(公告)号：WO2010042525A9
公开(公告)日：2010-11-18
申请号：PCT/US2009059706
申请日：2009-10-06
申请人： SOMALOGIC INC , GOLD LARRY , STANTON MARTY , BRODY EDWARD N , OSTROFF RACHEL M , ZICHI DOMINIC , STEWART ALEX A E
发明人： GOLD LARRY , STANTON MARTY , BRODY EDWARD N , OSTROFF RACHEL M , ZICHI DOMINIC , STEWART ALEX A E
IPC分类号： G06G7/58 , G01N33/50
CPC分类号： G01N33/57449 , G06F19/24
摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.
摘要翻译：本申请包括用于检测和诊断卵巢癌的生物标志物，方法，装置，试剂，系统和试剂盒。在一个方面，本申请提供了可以单独或以各种组合使用来诊断卵巢癌或允许盆腔肿块鉴别诊断为良性或恶性的生物标志物。另一方面，提供了用于诊断个体卵巢癌的方法，其中所述方法包括在来自个体的生物样品中检测对应于选自表1中提供的生物标记组中的至少一种生物标记物的至少一种生物标记物值其中所述个体被分类为患有卵巢癌，或基于所述至少一个生物标志物值确定所述个体患有卵巢癌的可能性。

2. 发明申请

WO2012047618A2 MESOTHELIOMA BIOMARKERS AND USES THEREOF 审中-公开
标题翻译： MESOTHELIOMA生物标记及其用途
公开(公告)号：WO2012047618A2
公开(公告)日：2012-04-12
申请号：PCT/US2011053377
申请日：2011-09-27
申请人： SOMALOGIC INC , OSTROFF RACHEL M , STEWART ALEX A E , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N , NIKRAD MALTI , RIEL-MEHAN MICHAEL
发明人： OSTROFF RACHEL M , STEWART ALEX A E , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N , NIKRAD MALTI , RIEL-MEHAN MICHAEL
IPC分类号： C40B30/04 , C40B40/10
CPC分类号： C12Q1/6886 , C12Q2600/158 , G01N33/57407 , G01N2800/50
摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and mesothelioma specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or mesothelioma specifically. In another aspect, methods are provided for diagnosing mesothelioma in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having mesothelioma, or the likelihood of the individual having mesothelioma is determined, based on the at least one biomarker value. In a further aspect, methods are provided for diagnosing cancer generally in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer generally, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.
摘要翻译：本公开内容包括用于特异性检测和诊断癌症和间皮瘤的生物标志物，方法，装置，试剂，系统和试剂盒。在一个方面，本公开提供了可以单独使用或以各种组合使用以生物标志物来诊断癌症或特异性间皮瘤。在另一方面，提供了用于诊断个体间皮瘤的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于选自表1中提供的生物标志物组的至少一种生物标志物的生物标记值，其中所述个体被分类为具有间皮瘤，或者所述个体具有间皮瘤的可能性基于所述至少一个生物标志物值被确定。在另一方面，提供了用于一般在个体中诊断癌症的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于至少一种选自表中提供的生物标志物的生物标志物的生物标记值 19，其中，基于所述至少一种生物标记值，将所述个体一般分类为具有癌症或确定患有癌症的个体的可能性。

3. 发明申请

WO2013062515A3 LUNG CANCER BIOMARKERS AND USES THEREOF 审中-公开
标题翻译：肺癌生物标志物及其用途
公开(公告)号：WO2013062515A3
公开(公告)日：2014-04-17
申请号：PCT/US2011057499
申请日：2011-10-24
申请人： SOMALOGIC INC , RIEL-MEHAN MICHAEL , STEWART ALEX A E , OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N
发明人： RIEL-MEHAN MICHAEL , STEWART ALEX A E , OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N
IPC分类号： G01N33/574
CPC分类号： G01N33/57423 , G01N2800/60
摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits tor the detection and diagnosis of non-small cell lung cancer and general cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose non-small cell lung cancer or general cancer. In another aspect, methods are provided for diagnosing non-small cell lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.
摘要翻译：本申请包括非小细胞肺癌和一般癌症的检测和诊断的生物标志物，方法，装置，试剂，系统和试剂盒。在一个方面，本申请提供可以单独使用或以各种组合使用以诊断非小细胞肺癌或一般癌症的生物标志物。在另一方面，提供了用于诊断个体中的非小细胞肺癌的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于选自生物标志物组的至少一种生物标志物的生物标记值如表1所示，其中，基于至少一种生物标志物值，将个体分类为具有肺癌或确定患有肺癌的个体的可能性。

4. 发明申请

WO2013028807A2 RENAL CELL CARCINOMA BIOMARKERS AND USES THEREOF 审中-公开
标题翻译：肾细胞癌细胞生物标志物及其用途
公开(公告)号：WO2013028807A2
公开(公告)日：2013-02-28
申请号：PCT/US2012051944
申请日：2012-08-22
申请人： SOMALOGIC INC , OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , RIEL-MEHAN MICHAEL , BRODY EDWARD N , STEWART ALEX A E , KATO SHINTARO
发明人： OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , RIEL-MEHAN MICHAEL , BRODY EDWARD N , STEWART ALEX A E , KATO SHINTARO
IPC分类号： C40B30/04 , C12Q1/68 , C40B40/06 , C40B40/10 , G01N33/574 , G06F19/00
CPC分类号： G01N33/57438 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G01N2333/4703 , G01N2333/4706 , G01N2333/521 , G01N2333/70503 , G01N2333/78 , G01N2333/805 , G01N2333/8121 , G01N2333/96433 , G01N2333/96494 , G06F19/20
摘要： The subject disclosure concerns methods for evaluation of renal cell carcinoma (RCC). Such methods include a method of determining of a diagnosis of the individual as having or not having RCC; determination of a prognosis of a future course of RCC; determination of disease burden; or determination of recurrence of RCC in an individual who had been apparently cured of RCC. The methods each involve the detection of the value of at least one biomarker of Table 1. The biomarker value is used, in some of the methods, to determine whether the individual does or does not demonstrate evidence of disease, and in another method, to determine the degree or a score indicative of the individual's extent of disease.
摘要翻译：本发明涉及肾细胞癌（RCC）评估方法。这种方法包括确定个体具有或不具有RCC的诊断的方法; 确定RCC未来过程的预后; 确定疾病负担; 或确定RCC明显治愈RCC的个体复发。所述方法各自涉及检测表1的至少一种生物标志物的值。在一些方法中，使用生物标志物值来确定个体是否表现出疾病的证据，并且在另一种方法中，确定指示个体疾病程度的程度或得分。

5. 发明公开

EP2622104A4 MESOTHELIOMA BIOMARKERS AND USES THEREOF 审中-公开
标题翻译：对于间皮瘤生物标记及其用途
公开(公告)号：EP2622104A4
公开(公告)日：2015-04-15
申请号：EP11831270
申请日：2011-09-27
申请人： SOMALOGIC INC
发明人： OSTROFF RACHEL M , STEWART ALEX A E , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N , NIKRAD MALTI , RIEL-MEHAN MICHAEL
IPC分类号： C12Q1/68 , G01N33/53 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/158 , G01N33/57407 , G01N2800/50

6. 发明公开

EP2771692A4 LUNG CANCER BIOMARKERS AND USES THEREOF 有权转让
标题翻译：生物标志物用于肺癌和使用
公开(公告)号：EP2771692A4
公开(公告)日：2015-08-26
申请号：EP11874668
申请日：2011-10-24
申请人： SOMALOGIC INC
发明人： RIEL-MEHAN MICHAEL , STEWART ALEX A E , OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N
IPC分类号： G01N33/574
CPC分类号： G01N33/57423 , G01N2800/60
摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer and general cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose non-small cell lung cancer or general cancer. In another aspect, methods are provided for diagnosing non-small cell lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.
摘要翻译：本申请包括用于非小细胞肺癌和一般癌症的检测和诊断的生物标志物，方法，装置，试剂，系统和试剂盒。一方面，本申请提供可以单独使用或以各种组合使用以诊断非小细胞肺癌或一般癌症的生物标志物。在另一方面，提供了用于诊断个体中的非小细胞肺癌的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于选自生物标志物组的生物标志物的生物标记值提供于表1中，其中基于至少一种生物标志物值将个体分类为具有肺癌或确定患有肺癌的个体的可能性。在另一方面，提供了用于诊断个体癌症的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于选自表19中提供的生物标志物组的至少一种生物标志物的生物标记值，其中基于所述至少一种生物标志物值将所述个体分类为具有癌症或确定患有癌症的个体的可能性。

7. 发明公开

EP2350917A4 OVARIAN CANCER BIOMARKERS AND USES THEREOF 审中-公开
标题翻译：卵巢癌生物标志物及其用途
公开(公告)号：EP2350917A4
公开(公告)日：2012-06-06
申请号：EP09819761
申请日：2009-10-06
申请人： SOMALOGIC INC
发明人： GOLD LARRY , STANTON MARTY , BRODY EDWARD N , OSTROFF RACHEL M , ZICHI DOMINIC , STEWART ALEX A E
IPC分类号： G06G7/58 , G01N33/50
CPC分类号： G01N33/57449 , G06F19/24

8. 发明专利

CA3006793C NON-SMALL CELL LUNG CANCER BIOMARKERS AND USES THEREOF 未知
公开(公告)号：CA3006793C
公开(公告)日：2020-02-18
申请号：CA3006793
申请日：2011-10-24
申请人： SOMALOGIC INC
发明人： RIEL-MEHAN MICHAEL , STEWART ALEX A E , OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N
IPC分类号： G01N33/574
摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose non-small cell lung cancer. In another aspect, methods are provided for diagnosing non-small cell lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to chordin-like 1 in combination with at least one other biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

9. 发明专利

CA2847188C NON-SMALL CELL LUNG CANCER BIOMARKERS AND USES THEREOF 未知
公开(公告)号：CA2847188C
公开(公告)日：2020-02-18
申请号：CA2847188
申请日：2011-10-24
申请人： SOMALOGIC INC
发明人： RIEL-MEHAN MICHAEL , STEWART ALEX A E , OSTROFF RACHEL M , WILLIAMS STEPHEN ALARIC , BRODY EDWARD N
IPC分类号： G01N33/53 , C12Q1/68 , C12Q1/6809 , C12Q1/6837 , C12Q1/6886 , C40B30/04 , G01N33/48 , G01N33/574 , G16B25/10
摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose non-small cell lung cancer. In another aspect, methods are provided for diagnosing non-small cell lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to carbonic anhydrase VI in combination with at least one other biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.

10. 发明专利

AU2013202112B2 Cardiovascular risk event prediction and uses thereof 未知
公开(公告)号：AU2013202112B2
公开(公告)日：2015-09-24
申请号：AU2013202112
申请日：2012-09-28
申请人： SOMALOGIC INC
发明人： GILL ROSALYNN DIANNE , WILLIAMS STEPHEN ALARIC , STEWART ALEX A E , MEHLER ROBERT , FOREMAN TRUDI , SINGER BRITTA
IPC分类号： G01N33/48 , G01N33/52
摘要： Biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) event within 5 years are disclosed. The biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. The methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value, the biomarker being selected from a group of biomarkers.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式